Neuroscience isn't currently one of the top strategic R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting. The UK-headquartered pharma group is ...

Energy and marine consultancy ABL has secured new five-year contracts with long-term client Woodside Energy that expands its existing workscope outside of Australia. ABL has been awarded a global ...

Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific antibodies. ABL Bio will receive an upfront payment and potential milestone ...

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple therapeutics using the Grabody-B platform. Under the terms announced Nov. 12, ...

ABL Bio said on the 12th that it signed a technology transfer and joint research and development agreement with U.S.-based Eli Lilly for the "Grabody-B" platform, a technology that penetrates the ...

Progress Software Corporation (NASDAQ:PRGS) is one of the most undervalued technology stocks to buy according to analysts. On September 29, Progress Software announced the early customer review and ...

Progress Software Corporation (NASDAQ:PRGS) Q3 2025 Earnings Call Transcript September 29, 2025 Progress Software Corporation beats earnings expectations. Reported EPS is $1.5, expectations were $1.3.

Hello, and thank you for standing by. Welcome to Progress Software Third Quarter 2025 Earnings Conference Call. [Operator Instructions]. I would now like to hand the conference over to Michael ...

“Generic AI tools struggle with ABL due to limited training data and lack of domain context,” said John Ainsworth, EVP and General Manager, Application and Data Platform, Progress Software. “The ...

ABL Bio announced on the 9th that it has terminated the technology introduction contract signed with the domestic corporations IntoCell. The company explained the reason for the contract termination ...